Systematic review finds no consistent neuropsychiatric harm from GLP-1 agonists

The wire

1. 01The PRISMA-guided review of four randomized, nine longitudinal and one cross-sectional study found observational depression hazard ratios from 0.63 to 2.95 and suicide-related estimates from 0.27 to 2.06.
2. 02Prescribers fielding patient questions about mood and suicidality on GLP-1 agonists now have a pooled narrative synthesis showing no consistent randomized signal of worsening.
3. 03Certainty was low for depressive symptoms and very low for anxiety and suicide outcomes; manic or hypomanic symptoms were not systematically assessed across studies.

From the source

Neuropsychiatric Outcomes Associated with GLP-1 Receptor Agonists in Adults with Overweight or Obesity: A Systematic Review

Brain sciences · 2026 Aug 31 · Lubo C, Bustamante R, Quintana L et al.